This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ojeda E, Garcia-Bustos J, Aguado MJ et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Blood 1999; 93: 3565.
Faucher C, Le Corroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533–536.
Cetkovsky P, Koza V, Jindra P et al. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transplant 1997; 20: 639–641.
Bence-Bruckler I, Bredeson C, Atkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965–969.
Haylock DN, To LB, Dowse TL et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80: 1405–1414.
Canales M, Ojeda E, Arrieta R et al. Influence of conditioning regimen on haematopoietic reconstitution in patients following PBPC transplantation. Proc Int Soc Haematol 1997; 88: 88 (abstract P-118).
Ojeda E, Garcia-Bustos J, Aguado MJ et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999; 24: 601–607.
Lee SM, Radford JA, Dobson L et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294–1299.
Piccirillo N, Sica S, Laurenti L et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1999; 23: 1245–1250.
Verma A, Pedicano J, Trifilio S et al. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 2004; 33: 715–719.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Canales, M., Hernández-Navarro, F. G-CSF or not G-CSF? That is the question. Bone Marrow Transplant 34, 557 (2004). https://doi.org/10.1038/sj.bmt.1704615
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704615